Hematopoietic Stem Cell Transplantation for Familial Hemophagocytic Lymphohistiocytosis and Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis in Japan
Hematopoietic Stem Cell Transplantation for Familial Hemophagocytic Lymphohistiocytosis and Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis in Japan
复制标题
DOI:
10.1002/pbc.22310
复制
发表时间:
2010-02-01
影响因子:
3.2
通讯作者:
Hara, Toshiro
中科院分区:
文献类型:
--
作者:
Ohga, Shouichi;Kudo, Kazuko;Hara, Toshiro
Background. Post-transplant outcomes of hemophagocytic lymphohistiocytosis (HLH) patients were analyzed in Japan where Epstein-Barr virus (EBV)-associated severe forms are problematic. Methods. Fifty-seven patients (43 familial HLH [12 FHL2, 11 FHL3, 20 undefined], 14 EBV-HLH) who Underwent Stem Cell transplantation (SCT) between 1995 and 2005 were enrolled based oil the nationwide registration. Results. Fifty-seven patients underwent 61 SCTs, including 4 consecutive SCTs. SCTs were employed using allogeneic donors in 93% of cases (allo 53, twin 1, auto 3). Unrelated donor cord blood transplantation (UCBT) was employed in half of cases (21 FHL, 7 EBV-HLH). Reduced intensity conditioning was used in 26% of cases. The 10-year overall Survival rates (rnedian +/- SE%) were 65.0 +/- 7.9%. in FHL and 85.7 +/- 9.4%. in EBV-HLH patients, respectively. The Survival of UCBT recipients was >65%. in both FHL and EBV-HLH patients. Three Out Of four patients were alive with Successful engraftment after second UCBT. FHL patients showed a Poorer Outcome due to early treatment-related deaths (